Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan.

<h4>Objectives</h4>The aim of this study was to examine the cost-effectiveness of branded and authorized generic (AG) celecoxib for chronic pain patients with osteoarthritis (OA), rheumatoid arthritis (RA), and low back pain (LBP), using real-world cost information for loxoprofen and pha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yusuke Karasawa, Isao Kamae, Kazutaka Nozawa, Shigeki Zeniya, Tatsunori Murata, Satoshi Soen, Choitsu Sakamoto
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a82f2f647e3a4de9bc76e1b060bb65d1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a82f2f647e3a4de9bc76e1b060bb65d1
record_format	dspace
spelling	oai:doaj.org-article:a82f2f647e3a4de9bc76e1b060bb65d12021-12-02T20:15:37ZCost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan.1932-620310.1371/journal.pone.0253547https://doaj.org/article/a82f2f647e3a4de9bc76e1b060bb65d12021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0253547https://doaj.org/toc/1932-6203<h4>Objectives</h4>The aim of this study was to examine the cost-effectiveness of branded and authorized generic (AG) celecoxib for chronic pain patients with osteoarthritis (OA), rheumatoid arthritis (RA), and low back pain (LBP), using real-world cost information for loxoprofen and pharmacotherapy for gastrointestinal bleeding.<h4>Methods</h4>This cost-effectiveness analysis was performed as a long-term simulation using the Markov model from the Japanese public healthcare payer's perspective. The analysis was conducted using loxoprofen with real-world weighted price by branded/generic distribution (hereinafter, loxoprofen with weighted price) as a comparator. In the model, we simulated the prognosis of patients with chronic pain by OA, RA, and LBP treated with loxoprofen or celecoxib, over a lifetime period.<h4>Results</h4>A cost-increase of 129,688 JPY (1,245.00 USD) for branded celecoxib and a cost-reduction of 6,268 JPY (60.17 USD) for AG celecoxib were recognized per patient in lifetime horizon, compared to loxoprofen with weighted price. No case was recognized to reverse the results of cost-saving by AG celecoxib in one-way sensitivity analysis. The incremental cost-effectiveness ratio of branded celecoxib attained 5,403,667 JPY/QALY (51,875.20 USD/QALY), compared to loxoprofen with the weighted price.<h4>Conclusion</h4>The current cost-effectiveness analysis for AG celecoxib revealed its good value for costs, considering the patients' future risk of gastrointestinal injury; also, the impact on costs due to AG celecoxib against loxoprofen will be small. It implies that the disadvantage of AG celecoxib being slightly more expensive than generic loxoprofen could be offset by the good cost-effectiveness during the prognosis.Yusuke KarasawaIsao KamaeKazutaka NozawaShigeki ZeniyaTatsunori MurataSatoshi SoenChoitsu SakamotoPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 7, p e0253547 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yusuke Karasawa Isao Kamae Kazutaka Nozawa Shigeki Zeniya Tatsunori Murata Satoshi Soen Choitsu Sakamoto Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan.
description	<h4>Objectives</h4>The aim of this study was to examine the cost-effectiveness of branded and authorized generic (AG) celecoxib for chronic pain patients with osteoarthritis (OA), rheumatoid arthritis (RA), and low back pain (LBP), using real-world cost information for loxoprofen and pharmacotherapy for gastrointestinal bleeding.<h4>Methods</h4>This cost-effectiveness analysis was performed as a long-term simulation using the Markov model from the Japanese public healthcare payer's perspective. The analysis was conducted using loxoprofen with real-world weighted price by branded/generic distribution (hereinafter, loxoprofen with weighted price) as a comparator. In the model, we simulated the prognosis of patients with chronic pain by OA, RA, and LBP treated with loxoprofen or celecoxib, over a lifetime period.<h4>Results</h4>A cost-increase of 129,688 JPY (1,245.00 USD) for branded celecoxib and a cost-reduction of 6,268 JPY (60.17 USD) for AG celecoxib were recognized per patient in lifetime horizon, compared to loxoprofen with weighted price. No case was recognized to reverse the results of cost-saving by AG celecoxib in one-way sensitivity analysis. The incremental cost-effectiveness ratio of branded celecoxib attained 5,403,667 JPY/QALY (51,875.20 USD/QALY), compared to loxoprofen with the weighted price.<h4>Conclusion</h4>The current cost-effectiveness analysis for AG celecoxib revealed its good value for costs, considering the patients' future risk of gastrointestinal injury; also, the impact on costs due to AG celecoxib against loxoprofen will be small. It implies that the disadvantage of AG celecoxib being slightly more expensive than generic loxoprofen could be offset by the good cost-effectiveness during the prognosis.
format	article
author	Yusuke Karasawa Isao Kamae Kazutaka Nozawa Shigeki Zeniya Tatsunori Murata Satoshi Soen Choitsu Sakamoto
author_facet	Yusuke Karasawa Isao Kamae Kazutaka Nozawa Shigeki Zeniya Tatsunori Murata Satoshi Soen Choitsu Sakamoto
author_sort	Yusuke Karasawa
title	Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan.
title_short	Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan.
title_full	Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan.
title_fullStr	Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan.
title_full_unstemmed	Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan.
title_sort	cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in japan.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/a82f2f647e3a4de9bc76e1b060bb65d1
work_keys_str_mv	AT yusukekarasawa costeffectivenessanalysisofbrandedandauthorizedgenericcelecoxibforpatientswithchronicpaininjapan AT isaokamae costeffectivenessanalysisofbrandedandauthorizedgenericcelecoxibforpatientswithchronicpaininjapan AT kazutakanozawa costeffectivenessanalysisofbrandedandauthorizedgenericcelecoxibforpatientswithchronicpaininjapan AT shigekizeniya costeffectivenessanalysisofbrandedandauthorizedgenericcelecoxibforpatientswithchronicpaininjapan AT tatsunorimurata costeffectivenessanalysisofbrandedandauthorizedgenericcelecoxibforpatientswithchronicpaininjapan AT satoshisoen costeffectivenessanalysisofbrandedandauthorizedgenericcelecoxibforpatientswithchronicpaininjapan AT choitsusakamoto costeffectivenessanalysisofbrandedandauthorizedgenericcelecoxibforpatientswithchronicpaininjapan
_version_	1718374545149132800

Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan.

Ejemplares similares